양극성 장애 및 치료 시장 : 시장 규모, 점유율, 동향, 성장 분석 보고서(2026-2034년)

The global bipolar disorder and treatment market size is expected to reach USD 9.58 Billion in 2034 from USD 6.52 Billion in 2025, growing at a CAGR of 4.36 during 2026-2034.This market is witnessing steady growth driven by the increasing prevalence of mental health disorders and growing awareness about bipolar disorder. Bipolar disorder is a chronic condition that requires long-term management through medication and therapy. The rising focus on mental health and the expansion of healthcare services are significantly contributing to market growth.

Key drivers include increasing healthcare awareness, advancements in psychiatric treatments, and the growing acceptance of mental health care. Pharmaceutical companies are developing new medications with improved efficacy and reduced side effects. The integration of digital health solutions, such as telemedicine and mobile health applications, is enhancing patient access to treatment. Additionally, government initiatives promoting mental health awareness are supporting market growth.

Future prospects for this market remain promising, with continuous innovation in treatment approaches and patient care models. The development of personalized therapies and digital mental health solutions will enhance treatment outcomes. Emerging markets are expected to offer significant growth opportunities due to improving healthcare access. As the focus on mental health continues to grow globally, the bipolar disorder and treatment market is poised for sustained expansion.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Drug Class

• Mood Stabilizers
• Anticonvulsants
• Anti-Psychotic Drugs
• Anti-Depressant Drugs
• Anti-Anxiety Drugs
• Other Drug Classes

By Route Of Administration

• Oral
• Parenteral
• Other Routes Of Administration

By Mechanism Of Action

• Selective Serotonin Reuptake Inhibitors
• Serotonin Norepinephrine Reuptake Inhibitors
• Tricyclic Antidepressant Drugs
• Beta Blockers
• Other Mechanisms Of Actions

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis, Otsuka Holdings, Pfizer, Sunovion Pharmaceuticals, Teva Pharmaceutical, Validus Pharmaceuticals.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BIPOLAR DISORDER AND TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Mood Stabilizers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Anticonvulsants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Anti-Psychotic Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Anti-Depressant Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Anti-Anxiety Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BIPOLAR DISORDER AND TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Other Routes Of Administration Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BIPOLAR DISORDER AND TREATMENT MARKET: BY MECHANISM OF ACTION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Mechanism Of Action
• 6.2. Selective Serotonin Reuptake Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Serotonin Norepinephrine Reuptake Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Tricyclic Antidepressant Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Beta Blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Other Mechanisms Of Actions Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BIPOLAR DISORDER AND TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BIPOLAR DISORDER AND TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Drug Class
  • 8.2.2 By Route Of Administration
  • 8.2.3 By Mechanism Of Action
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Drug Class
  • 8.3.2 By Route Of Administration
  • 8.3.3 By Mechanism Of Action
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Drug Class
  • 8.4.2 By Route Of Administration
  • 8.4.3 By Mechanism Of Action
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Drug Class
  • 8.5.2 By Route Of Administration
  • 8.5.3 By Mechanism Of Action
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Drug Class
  • 8.6.2 By Route Of Administration
  • 8.6.3 By Mechanism Of Action
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL BIPOLAR DISORDER AND TREATMENT INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 AbbVie
  • 10.2.2 AstraZeneca
  • 10.2.3 Bristol-Myers Squibb
  • 10.2.4 Eli Lilly
  • 10.2.5 GlaxoSmithKline
  • 10.2.6 Janssen Pharmaceuticals
  • 10.2.7 Novartis
  • 10.2.8 Otsuka Holdings
  • 10.2.9 Pfizer
  • 10.2.10 Sunovion Pharmaceuticals
  • 10.2.11 Teva Pharmaceutical
  • 10.2.12 Validus Pharmaceuticals